Cargando…
Critical Care Admission of an HIV Patient with Diabetic Ketoacidosis Secondary to Pembrolizumab
BACKGROUND: Pembrolizumab is a checkpoint inhibitor that targets the programmed cell death-1 receptor (PD-1) and has shown to be effective against several malignancies, including lung cancer. However, life-threatening immune-related adverse events can result from these immunotherapy treatments. Case...
Autores principales: | Cuenca, John A., Laserna, Andres, Reyes, María P., Nates, Joseph L., Botz, Gregory H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132356/ https://www.ncbi.nlm.nih.gov/pubmed/32274219 http://dx.doi.org/10.1155/2020/8671530 |
Ejemplares similares
-
Pembrolizumab-Induced Diabetic Ketoacidosis: A Review of Critical Care Case
por: Sankar, Keerthana, et al.
Publicado: (2021) -
Diabetic Ketoacidosis Secondary to New Onset Type 1 Diabetes Mellitus Related to Pembrolizumab Therapy
por: Hernandez, Andrea, et al.
Publicado: (2021) -
ODP159 A Rare Case of Pembrolizumab Induced Diabetic Ketoacidosis
por: Durrani, Jawahar, et al.
Publicado: (2022) -
Implementation of a Diabetes Educator Care Model to Reduce Paediatric Admission for Diabetic Ketoacidosis
por: Deeb, Asma, et al.
Publicado: (2016) -
Pembrolizumab-Induced Diabetes Mellitus Presenting as Diabetic Ketoacidosis in a Patient With Metastatic Colonic Adenocarcinoma
por: Kichloo, Asim, et al.
Publicado: (2020)